A Randomized Trial of Low-Dose Bevacizumab vs Laser for Type 1 ROP
Status:
Recruiting
Trial end date:
2029-04-01
Target enrollment:
Participant gender:
Summary
This randomized clinical trial will compare retinal outcomes with low-dose intravitreous
bevacizumab (0.063 mg) versus laser photocoagulation as treatment for infants with type 1
retinopathy of prematurity (ROP).
The study also will assess neurodevelopment, refractive error, visual acuity, and peripheral
visual fields.
Phase:
Phase 3
Details
Lead Sponsor:
Jaeb Center for Health Research
Collaborators:
National Eye Institute (NEI) Pediatric Eye Disease Investigator Group